Boards of Directors Take Action in 2001
The ISPOR 2000-2001 and 2001-2002 Boards of Directors had a busy 2001. The
Boards met seven times (5 teleconferences and 2 face-to-face meetings). The
Boards approved the following:
ISPOR By-laws / Policy & Procedures /
- By-laws amendment that the Treasurer of the
Society is a voting Board member, who is appointed by the Board for up to
two 3-year terms. See the ISPOR website at http://www.ispor.org/
by_laws.htm for details.
ISPOR Policies & Procedures
- The Value in Health Policies and Procedures
document. For a copy of the Value in Health Policies and Procedures, email
your request to email@example.com
- The restructure of the Value in Health
Management Advisory Board (MAB), which has an oversight responsibility for
the management of Value in Health. The committee will now consist of a
3-member team, each with a 3-year term. Board appointees are Bryan Luce (1
year), Jon Clouse (2 years), Brenda Motheral (3 years).
- The length of term for the Value in Health
Editor-in-Chief contract is 4 years.
- A Value in Health Editor-in-Chief open
solicitation process, which would occur at the end of each Value in Health
Editor-in-Chief contract term, with the understanding that an incumbent
Editor-in-Chief can respond to the solicitation, if interested.
- Jean Paul Gagnon appointed Treasurer for a
second 3-year term.
- Protocol development for the selection of
the next ISPOR Treasurer (involving an open solicitation to the ISPOR
- A revised ISPOR Institutional Council
Standard Operating Procedure, which included a revised procedure for the
election and term of office of the Institutional Council Chair. This
position is now consistent with other ISPOR leadership positions.
- The creation of the ISPOR Strategic
Outreach Committee with Mike Drummond as chair. The mission of this new
committee is to follow changes in other societies whose membership overlaps
that of ISPOR and to consider areas where we might collaborate or even
consolidate, with the goal of developing within ISPOR a broader, more
effective membership base and greater influence of healthcare
- All ISPOR Committee and Task Force Chairs
(if not employed by a pharmaceutical/device/diagnostic company or contract
research organization) receive complimentary Annual Meeting or Annual
European Congress registration.
- The evaluation of all ISPOR Committee and
Task Forces each year prior to the end of the ISPOR Leadership year (July 1
to June 30) to determine if the Committee or Task Force should be
discontinued for the next ISPOR Leadership year.
- Embraced the ECHO model for outcomes
research (i.e. ECHO=economic, clinical, and humanistic outcomes) and
suggested that, perhaps in the future, the acronym, ISPOR, should be
presented as: ISpOR (with p for population) to support the breadth of the
scope of the Society. The Board also agreed that the scope and mission of
Value in Health should be consistent with the mission and scope of the
- Legg Mason, and its initial portfolio, as
the Financial Manager/Plan for the ISPOR long-term funds ($300,000).
- he ISPOR Financial Auditor’s
recommendations (as published in the ISPOR 2000 Financial Audit Report).
For a copy of the Financial Audit Report, contact
- No in-kind contributions are accepted in
- The Blackwell Science Value in Health 2002
|Award / Recognition
Conference / Other Initiatives Actions:
- Development of a symposium on the use of
pharmacoeconomic information in formulary decisions for the AMCP Fall
Meeting to be held October 2001 in Dallas, Texas, USA.
- Printing of the Annual Meeting and European
Congress Contributed Workshop Abstracts in the meeting program brochure and
published at the ISPOR website.
- Financial support of the PRO
(Patient-Reported Outcomes) Harmonization Initiatives (a joint effort of
ISPOR, ERIQA, PhRMA HOC, ISOQOL, and FDA).
- Development of a protocol on how to handle
solicitation of funds from outside organizations.
- Concurred with the ISPOR LEXICON Second
Edition outline developed by Chris Pashos. For more information contact
- Terminated the CEA & Managed Care:
Maintaining Health of Population Conference Proceeding project.
- Endorsed the following Statement of the
World Association of Medical Editors (WAME) published in this issue of
ISPOR NEWS and at the ISPOR website at:
- Responded to a (advisory) letter from
Blackwell Science concerning the journal’s financial issues. As a
consequence, the MAB will: a) meet with representatives of Blackwell
Science to discuss ViH expectations both short-term and long-term;
b) develop a Value in Health Survey to determine the expectations of the
ISPOR members; c) develop a ViH Supplement strategy.
- Name change from ISPOR NEWS to ISPOR
- Endorsed the ISPOR Commissioned Paper
Initiative: ‘Moving beyond Budget Mentality in Europe’ with the
understanding that the commissioned papers will be submitted to Value in
Health as first choice.
|Committee / Task Force
- Task Force Reports are published in Value
in Health, as a ‘within book’ manuscript according to the review policies
and procedure determined by ViH Editor-in-Chief and that the ISPOR Board of
Directors must approve publication of the Reports in any non-ISPOR
- Requested that the Quality of Life Special
Interest Group and the Health Science Committee Quality of Life Task Force
define what actions to be taken with respect to the WHO initiative to
standardize the measurement of health status of national and international
The following ISPOR Student Chapter:
• ISPOR Student Chapter - Florida Agricultural and Mechanical University.
• ISPOR Student Chapter - The Ohio State University.
• ISPOR Student Chapter – West Virginia University.
• ISPOR Student Chapter – University of New Mexico.
• ISPOR Student Chapter – University of Toledo.
• ISPOR Student Chapter – University of Dundee, Dundee, Scotland.
• The Chinese Chapter of the International Society for Pharmacoeconomics and
Outcomes Research as an official regional chapter of ISPOR.
- The following statement concerning the AMCP
Format for Formulary Submissions:
The International Society for Pharmacoeconomics and Outcomes Research Board
of Directors views the Academy of Managed Care Pharmacy document, “A Format
of Submission of Clinical and Economic Data in Support of Formulary
Consideration by Managed Health Care Systems in the United States” as
consistent with the mission of the Society, which is to translate
pharmacoeconomics and outcomes research into practice to insure that
society allocates scarce health care resources wisely, fairly, and
efficiently. In addition, the AMCP initiative is consistent with a recent
“Bridging the Gap” initiative (i.e. bridging the gap between the
development of pharmacoeconomics and outcomes research evidence and the
integration of the resulting evidence with drug formulary decision-making).
Consequently, ISPOR welcomes the introduction of the guidelines based, in
part, on a complete review of evidence, including health economic and
patient-based outcomes, as a positive step toward the goal of
evidence-based decision-making in health care. There are various guidelines
for submission of pharmacoeconomic information around the world, most of
which are fundamentally similar to the AMCP format. Although the Society
does not endorse any particular guidelines, it does endorse the development
of explicit guidelines for decision-making based on evidence of health
outcomes. Further, ISPOR expresses interest in participating in some
meaningful way in the evaluation of the issues associated with the
construction and use of AMCP guidelines. For instance, ISPOR's meetings and
symposia can be useful to clarify issues and to improve methodology. ISPOR
is also committed to assisting health care decision-makers and
practitioners in the field better understand the basics of
pharmacoeconomics and outcomes analyses including their interpretation as a
means to providing more efficient health care. ISPOR views guidelines, such
as those issued by the Academy, to be fluid documents that will change over
time with improvements in methods, more input and understanding from
consumers and decision-makers as well as changing health care delivery and
data systems. ISPOR offers its services and access to its members to
address specific issues such as those addressed above.
- Responded to the National Association of
Insurance Commissioners (NAIC)’ Health Carrier Prescription Drug Benefit
Management Model Act as well as ISPOR testified at the NAIC meeting on the
Model Act. For responses sent to the NAIC, see: